Universität und Industrie
Partner in der pharmazeutischen Forschung : Seminare in Europa 1992-1994
| LEADER | cam a22 u 4500 | ||
|---|---|---|---|
| 001 | 273701282 | ||
| 003 | CHVBK | ||
| 005 | 20201020194018.0 | ||
| 008 | 130818s1995 sz |||||||||| 00 |ger d | ||
| 020 | |a 3-907770-35-8 | ||
| 035 | |a (IDSBB)001110147 | ||
| 035 | |a (SNL)991002119129703976 | ||
| 035 | |a (ALEX)9914282824101791 | ||
| 035 | |a (IDSLU)000093693 | ||
| 035 | |a (NEBIS)001489353 | ||
| 035 | |a (RERO)2122087 | ||
| 035 | |a (Sz)47449-41snl_51 | ||
| 035 | |a (Sz)vtls000047449 | ||
| 035 | |a (Sz)000047449 | ||
| 037 | |a 71690 |b Editiones Roche | ||
| 040 | |a SzZuIDS BS/BE A100 |b ger |e kids | ||
| 072 | 7 | |a s1pa |2 rero | |
| 082 | 1 | |a 615 |2 15 | |
| 245 | 0 | 0 | |a Universität und Industrie |b Partner in der pharmazeutischen Forschung : Seminare in Europa 1992-1994 |c hrsg. von Jürgen Drews und Albert Fischli |
| 264 | 1 | |a Basel |b Editiones Roche |c [1995] | |
| 264 | 4 | |c © 1995 | |
| 300 | |a 203 S. |b Ill. |c 24 cm | ||
| 500 | |a Titel der engl. Ausg.: University and industry | ||
| 610 | 2 | 7 | |a Roche (Firma) |2 idszbz |
| 650 | 7 | |a HIV-Infektion |0 (DE-588)4203852-2 |2 gnd | |
| 650 | 7 | |a Immunmodulation |0 (DE-588)4315157-7 |2 gnd | |
| 650 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd | |
| 650 | 7 | |a Proteaseinhibitor |0 (DE-588)4130450-0 |2 gnd | |
| 650 | 7 | |a Retinoide |0 (DE-588)4177903-4 |2 gnd | |
| 650 | 7 | |a Tumor-Nekrose-Faktor |0 (DE-588)4202932-6 |2 gnd | |
| 650 | 7 | |a Forschung |2 idszbz | |
| 650 | 7 | |a EXPERIMENTELLE MEDIZIN + MEDIZINISCHE FORSCHUNG + MEDIZINISCHE MESSTECHNIK + MEDIZINISCHE VERSUCHE |x ger |0 (ETHUDK)000025845 |2 ethudk | |
| 650 | 7 | |a HIV-INFEKTION + AIDS (PATHOLOGIE) |x ger |0 (ETHUDK)000026064 |2 ethudk | |
| 650 | 7 | |a IMMUNREAKTION + IMMUNANTWORT (IMMUNOLOGIE) |x ger |0 (ETHUDK)000038618 |2 ethudk | |
| 650 | 7 | |a KREBSHEMMENDE ARZNEIMITTEL (PHARMAZIE) |x ger |0 (ETHUDK)000026738 |2 ethudk | |
| 650 | 7 | |a MEDIKAMENTE ZUR BEHANDLUNG VON AIDS |x ger |0 (ETHUDK)000045368 |2 ethudk | |
| 650 | 7 | |a PHARMAZEUTISCHE FORSCHUNG |x ger |0 (ETHUDK)000043315 |2 ethudk | |
| 650 | 7 | |a RETINOIDE (BIOCHEMIE) |x ger |0 (ETHUDK)000022615 |2 ethudk | |
| 650 | 7 | |a TUMORNEKROSEFAKTOR (IMMUNOLOGIE) |x ger |0 (ETHUDK)000040120 |2 ethudk | |
| 650 | 7 | |a collaboration |0 (RERO)A010066308 |2 rerovoc | |
| 650 | 7 | |a Industrie |0 (RERO)A021017052 |2 rero | |
| 650 | 7 | |a Médicaments |0 (RERO)A021002158 |2 rero | |
| 650 | 7 | |a Recherche |0 (RERO)A021004811 |2 rero | |
| 650 | 7 | |a Universités |0 (RERO)A021002926 |2 rero | |
| 655 | 7 | |a Aufsatzsammlung |2 gnd | |
| 655 | 7 | |a Aufsatzsammlung |2 idszbz | |
| 655 | 7 | |a Aufsatzsammlung |2 gnd-content | |
| 655 | 7 | |a Études diverses |0 (RERO)A022249905 |2 rero | |
| 690 | 7 | |B u |a Medizin |2 idsbb F1 | |
| 690 | 7 | |B u |a Forschung |2 idsbb F1 | |
| 690 | 7 | |B u |a Hoffmann - La Roche AG, B: Forschung. Aufsätze |2 idslu L1 | |
| 690 | 7 | |B u |a Pharmaforschung, B: Hoffmann - La Roche AG. Aufsätze |2 idslu L1 | |
| 690 | 7 | |B u |a Forschung, B: pharmazeutische: Hoffmann - La Roche AG. Aufsätze |2 idslu L1 | |
| 690 | 7 | |B u |a Biomedizin, B: Forschung: Hoffmann - La Roche AG. Aufsätze |2 idslu L1 | |
| 691 | 7 | |a 615.0 |2 snl local | |
| 691 | 7 | |a 615.1 |2 snl local | |
| 691 | 7 | |a sb |b 1995/13 |c 17 |2 snl-sb | |
| 691 | 7 | |B u |a PHARMAZEUTISCHE FORSCHUNG |z ger |u 615%001.891 |2 nebis E1 | |
| 691 | 7 | |B u |a RETINOIDE (BIOCHEMIE) |z ger |u 577.13,233.3 |2 nebis E1 | |
| 691 | 7 | |B u |a HIV-INFEKTION + AIDS (PATHOLOGIE) |z ger |u 616.988%578.828.8 |2 nebis E1 | |
| 691 | 7 | |B u |a MEDIKAMENTE ZUR BEHANDLUNG VON AIDS |z ger |u 615.281.8*1 |2 nebis E1 | |
| 691 | 7 | |B u |a EXPERIMENTELLE MEDIZIN + MEDIZINISCHE FORSCHUNG + MEDIZINISCHE MESSTECHNIK + MEDIZINISCHE VERSUCHE |z ger |u 61-08 |2 nebis E1 | |
| 691 | 7 | |B u |a IMMUNREAKTION + IMMUNANTWORT (IMMUNOLOGIE) |z ger |u 612.017.1,3 |2 nebis E1 | |
| 691 | 7 | |B u |a TUMORNEKROSEFAKTOR (IMMUNOLOGIE) |z ger |u 612.017.1,24.8 |2 nebis E1 | |
| 691 | 7 | |B u |a KREBSHEMMENDE ARZNEIMITTEL (PHARMAZIE) |z ger |u 615.277.3 |2 nebis E1 | |
| 691 | 7 | |B u |a PHARMACEUTICAL RESEARCH |z eng |u 615%001.891 |2 nebis E1 | |
| 691 | 7 | |B u |a RECHERCHE PHARMACEUTIQUE |z fre |u 615%001.891 |2 nebis E1 | |
| 691 | 7 | |B u |a RÉTINOÏDES (BIOCHIMIE) |z fre |u 577.13,233.3 |2 nebis E1 | |
| 691 | 7 | |B u |a RETINOIDS (BIOCHEMISTRY) |z eng |u 577.13,233.3 |2 nebis E1 | |
| 691 | 7 | |B u |a SIDA (SYNDROME IMMUNO-DEFICITAIRE ACQUIS) |z fre |u 616.988%578.828.8 |2 nebis E1 | |
| 691 | 7 | |B u |a HIV INFECTION + AIDS (PATHOLOGY) |z eng |u 616.988%578.828.8 |2 nebis E1 | |
| 691 | 7 | |B u |a MÉDICAMENTS CONTRE LE SIDA |z fre |u 615.281.8*1 |2 nebis E1 | |
| 691 | 7 | |B u |a ANTI-AIDS DRUGS |z eng |u 615.281.8*1 |2 nebis E1 | |
| 691 | 7 | |B u |a MÉDECINE EXPERIMENTALE + RECHERCHE MÉDICALE + MÉTHODES DE MESURE + EXPERIMENTATION MÉDICALE |z fre |u 61-08 |2 nebis E1 | |
| 691 | 7 | |B u |a EXPERIMENTAL MEDICINE + MEDICAL RESEARCH + MEDICAL MEASURING TECHNIQUES + MEDICAL EXPERIMENTS |z eng |u 61-08 |2 nebis E1 | |
| 691 | 7 | |B u |a RÉACTIONS IMMUNITAIRES + RÉPONSES IMMUNITAIRES (IMMUNOLOGIE) |z fre |u 612.017.1,3 |2 nebis E1 | |
| 691 | 7 | |B u |a IMMUNE REACTION + IMMUNE RESPONSE (IMMUNOLOGY) |z eng |u 612.017.1,3 |2 nebis E1 | |
| 691 | 7 | |B u |a TUMOR NECROSIS FACTOR (IMMNUNOLOGY) |z eng |u 612.017.1,24.8 |2 nebis E1 | |
| 691 | 7 | |B u |a FACTEUR DE NÉCROSE TUMORALE (IMMUNOLOGIE) |z fre |u 612.017.1,24.8 |2 nebis E1 | |
| 691 | 7 | |B u |a CARCINOSTATICS + ANTINEOPLASTICS + ONCOSTATICS + CANCER REMEDIES (PHARMACY) |z eng |u 615.277.3 |2 nebis E1 | |
| 691 | 7 | |B u |a ONCOSTATIQUES + CARCINOSTATIQUES + ANTINÉOPLASTIQUES (PHARMACIE) |z fre |u 615.277.3 |2 nebis E1 | |
| 700 | 1 | |a Fischli |D Albert | |
| 700 | 1 | |a Drews |D Jürgen | |
| 898 | |a BK020800 |b XK020000 |c XK020000 | ||
| 898 | |a BK020000 |b XK020000 |c XK020000 | ||
| 912 | 7 | |a pm |2 SzZuIDS BS/BE | |
| 912 | 7 | |a 33 |2 IDS LU | |
| 949 | |B SNL |F NB001 |b NB001 |j N 218904 |c NB10010 | ||
| 949 | |B IDSBB |F A100 |b A100 |c MAG |j UBH lt 13747 |x Akz: ba/uub-/g/95/L92177 | ||
| 949 | |B IDSBB |F B583 |b B583 |c MAG |j IMG CQA 2018 26 |s IMG QV 20,5 R673 |x NELB5831802 | ||
| 949 | |B IDSBB |F A304 |b A304 |c PR |j PHM Aa 519 |x NELA3041902 | ||
| 950 | |B IDSBB |P 700 |E 1- |a Fischli |D Albert | ||
| 950 | |B IDSBB |P 700 |E 1- |a Drews |D Jürgen | ||
| 950 | |B SNL |P 700 |E 1- |a Drews |D Jürgen | ||
| 950 | |B SNL |P 700 |E 1- |a Fischli |D Albert | ||
| 950 | |B SNL |P 710 |E 2- |a F. Hoffmann-La Roche AG |0 (DE-588)2118013-1 | ||
| 950 | |B ALEX |P 700 |E 1- |a Drews |D Jürgen | ||
| 950 | |B ALEX |P 700 |E 1- |a Fischli |D Albert | ||
| 950 | |B ALEX |P 710 |E 2- |a F. Hoffmann-La Roche AG | ||
| 950 | |B IDSLU |P 700 |E 1- |a Drews |D Jürgen | ||
| 950 | |B NEBIS |P 700 |E 1- |a Drews |D Jürgen | ||
| 950 | |B RERO |P 700 |E 1- |a Drews |D Jürgen |0 (IDREF)061093335 | ||